| Value | ₹56.00 Cr |
|---|
NSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹731.70
- Market cap
- ₹11,517 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.5×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Other merger & restructuring announcements
All →KS Smart Technologies Merger & Restructuring Worth ₹0.01 Cr
KS Smart Technologies reported completion of a foreign subsidiary's incorporation, KS Smart Global Inc. in USA, on 22 October 2026. Transaction amount is ₹0.01 Crore.
- Value
- ₹0.01 Cr
KS Smart Technologies Merger & Restructuring
KS Smart Technologies reported that its step-down subsidiary KS Smart Global Inc. was incorporated in Delaware, USA, on October 22, 2026. The initial share subscription is stated as up to USD 510, held 51% by KSSPL.
AXISCADES Technologies Merger & Restructuring
AXISCADES Technologies disclosed that its step-down subsidiary Ulosia Holding AG incorporated AKKODIS AXISCADES AEROSPACE CANADA INC. in Canada. No cash was invested by the listed entity, and no value is stated.
Sapphire Foods India Merger & Restructuring
Sapphire Foods received CCI approval under Section 31(1) for its proposed merger into Devyani International under a Scheme of Arrangement. The detailed CCI order is still awaited.
Aditya Ispat Merger & Restructuring
Aditya Ispat's steel slump sale to related party Jai Bapji Ispat now completes by 31 December 2026. Delay stems from pre-closing actions under the business transfer agreement.
Vahh Chemicals Merger & Restructuring Worth ₹0.1 Cr
VAHH Chemicals will incorporate Vedant Nutrition Limited as a wholly owned nutraceutical subsidiary with Rs 0.10 Crore cash. Incorporation is tentatively dated November 5, 2026.
- Value
- ₹0.10 Cr